S.No |
Study title |
Principal Investigator |
1. |
Principal Investigator An Open-Label, Multicenter Evaluation of the Long-Term Safety and Efficacy of Recombinant Human Coagulation Factor VIII Fusion Protein (rFVIIIFc) in the Prevention and Treatment of Bleeding Episodes in Previously Treated Subjects With Hemophilia A (ASPIRE) – Biogen Idec |
Dr. Fouzia. N.A |
2. |
Prospective, open-label, uncontrolled, phase III study to assess the efficacy and safety of Octafibrin for on-demand treatment of acute bleeding and to prevent bleeding during and after surgery in subjects with congenital fibrinogen deficiency (Octapharma) |
Dr. Fouzia. N.A |
3. |
Immunogenicity, Efficacy and Safety of Treatment with Human-cl rhFVIII in Previously Untreated Patients with Severe Haemophilia A (Protocol: GENA-05) - Octapharma |
Dr. Fouzia. N.A |
14. |
Extension Study for patient who completed GENA-05 (Nuprotect)-to investigate Immunogenicity, Efficacy & Safety of treatment with Human Cl-rhFVIII(GENA-15); Protocol: GENA-15 |
Dr. Fouzia. N.A |